CR20190551A - Compuestos y composiciones para inducir la condrogénesis - Google Patents

Compuestos y composiciones para inducir la condrogénesis

Info

Publication number
CR20190551A
CR20190551A CR20190551A CR20190551A CR20190551A CR 20190551 A CR20190551 A CR 20190551A CR 20190551 A CR20190551 A CR 20190551A CR 20190551 A CR20190551 A CR 20190551A CR 20190551 A CR20190551 A CR 20190551A
Authority
CR
Costa Rica
Prior art keywords
compounds
compositions
inducing
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CR20190551A
Other languages
English (en)
Inventor
Ha-Soon Choi
Bao Nguyen
Zhicheng Wang
Jiqing Jiang
James Paul Lajiness
Hank Michael James Petrassi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20190551A publication Critical patent/CR20190551A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Abstract

La presente invención proporciona un compuesto de Fórmula (I) o una de sus sales farmacéuticamente aceptables; (I) o una de sus sales farmacéuticamente aceptables, uno de sus tautómeros, o uno de sus estereoisómeros, donde las variables son como se definen en la presente solicitud. La presente invención proporciona además composiciones farmacéuticas que comprenden dichos compuestos; y métodos para usar dichos compuestos para tratar el daño o la lesión articular en un mamífero, para inducir la producción de cartílago hialino o para inducir la diferenciación de células progenitoras condrogénicas en condrocitos maduros.
CR20190551A 2017-06-09 2018-06-07 Compuestos y composiciones para inducir la condrogénesis CR20190551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Publications (1)

Publication Number Publication Date
CR20190551A true CR20190551A (es) 2020-01-28

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190551A CR20190551A (es) 2017-06-09 2018-06-07 Compuestos y composiciones para inducir la condrogénesis

Country Status (35)

Country Link
US (3) US11091499B2 (es)
EP (3) EP3915994B9 (es)
JP (2) JP7229945B2 (es)
KR (1) KR102656524B1 (es)
CN (1) CN110719913B (es)
AR (1) AR113227A1 (es)
AU (1) AU2018279306C1 (es)
BR (1) BR112019025866A2 (es)
CA (1) CA3063985A1 (es)
CL (1) CL2019003564A1 (es)
CO (1) CO2019013706A2 (es)
CR (1) CR20190551A (es)
CU (1) CU24577B1 (es)
DK (1) DK3915994T3 (es)
DO (1) DOP2019000305A (es)
EA (1) EA201992858A1 (es)
EC (1) ECSP19086712A (es)
FI (1) FI3915994T3 (es)
HR (1) HRP20240155T1 (es)
IL (2) IL300755A (es)
JO (1) JOP20190282A1 (es)
LT (1) LT3915994T (es)
MA (2) MA57022B1 (es)
MX (1) MX2019014757A (es)
NZ (1) NZ759434A (es)
PE (1) PE20200403A1 (es)
PH (1) PH12019502764A1 (es)
PT (1) PT3915994T (es)
RS (1) RS65161B1 (es)
SA (1) SA519410729B1 (es)
SI (1) SI3915994T1 (es)
TW (1) TWI782036B (es)
UY (1) UY37759A (es)
WO (1) WO2018225009A1 (es)
ZA (1) ZA201907358B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
WO2020115683A1 (en) * 2018-12-06 2020-06-11 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JP7427665B2 (ja) * 2018-12-06 2024-02-05 ノバルティス アーゲー 関節損傷を治療するための軟骨形成を誘導するための６－ヒドロキシ－８－オキサトリシクロ［３．２．１．０２，４］オクタン－２－カルボキサミド誘導体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272640T1 (de) * 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2757480A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
CA2767826C (en) 2009-07-14 2015-11-24 The Scripps Research Institute Mesenchymal stem cell differentiation using aniopoietin-like-3
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
KR102283996B1 (ko) * 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
AP2016009502A0 (en) 2014-05-13 2016-10-31 Novartis Ag Compounds and compositions for inducing chondrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) * 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
JP2020522550A (ja) 2020-07-30
HRP20240155T1 (hr) 2024-04-12
DK3915994T3 (da) 2024-02-19
MA50547A (fr) 2020-09-16
WO2018225009A1 (en) 2018-12-13
AU2018279306C1 (en) 2021-01-14
EP3634967A1 (en) 2020-04-15
RU2019144107A3 (es) 2021-07-30
PT3915994T (pt) 2024-02-15
UY37759A (es) 2019-01-31
CU24577B1 (es) 2022-02-04
JOP20190282A1 (ar) 2019-12-05
EP3915994A1 (en) 2021-12-01
TWI782036B (zh) 2022-11-01
US20230365580A1 (en) 2023-11-16
EP4299123A3 (en) 2024-04-03
JP7432778B2 (ja) 2024-02-16
AR113227A1 (es) 2020-02-19
US20210079010A1 (en) 2021-03-18
AU2018279306B2 (en) 2020-07-09
JP2023062064A (ja) 2023-05-02
JP7229945B2 (ja) 2023-02-28
NZ759434A (en) 2024-01-26
CA3063985A1 (en) 2018-12-13
AU2018279306A1 (en) 2019-12-05
IL271154A (en) 2020-01-30
RS65161B1 (sr) 2024-02-29
BR112019025866A2 (pt) 2020-07-14
PH12019502764A1 (en) 2020-07-13
KR20200013046A (ko) 2020-02-05
CN110719913B (zh) 2022-10-28
CL2019003564A1 (es) 2020-06-19
CN110719913A (zh) 2020-01-21
RU2019144107A (ru) 2021-07-09
CO2019013706A2 (es) 2020-04-01
IL300755A (en) 2023-04-01
FI3915994T3 (fi) 2024-02-14
PE20200403A1 (es) 2020-02-26
TW201902900A (zh) 2019-01-16
CU20190098A7 (es) 2020-10-20
IL271154B2 (en) 2023-07-01
US11753416B2 (en) 2023-09-12
EP4299123A2 (en) 2024-01-03
ECSP19086712A (es) 2019-12-27
LT3915994T (lt) 2024-02-26
EP3915994B9 (en) 2024-02-28
MX2019014757A (es) 2020-02-12
IL271154B1 (en) 2023-03-01
SI3915994T1 (sl) 2024-03-29
ZA201907358B (en) 2022-04-28
US11091499B2 (en) 2021-08-17
MA57022B1 (fr) 2024-02-29
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
US20210347784A1 (en) 2021-11-11
KR102656524B1 (ko) 2024-04-12
DOP2019000305A (es) 2019-01-15
SA519410729B1 (ar) 2022-07-03

Similar Documents

Publication Publication Date Title
PH12016502005B1 (en) Compounds and compositions for inducing chondrogenesis
PH12019502764A1 (en) Compounds and compositions for inducing chondrogenesis
TN2020000158A1 (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
SG10201908467RA (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
MX354175B (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MY199931A (en) 3-substituted propionic acids as alpha v integrin inhibitors
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
NZ726108A (en) Substituted dihydroisoquinolinone compounds
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
WO2017177004A8 (en) Tertiary amides and method of use
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2